News

PharmExec12h
Phase III Trials Show Merck’s Oral PCSK9 Inhibitor Significantly Reduces LDL-Cholesterol in Hyperlipidemia
Results from the Phase III CORALreef HeFH and CORALreef AddOn studies demonstrated tatistically significant and clinically ...
PharmExec10h
FDA Issues Refusal to File Letter for Axsome’s Novel Fibromyalgia Candidate
FDA concluded that AXS-14’s New Drug Application was not sufficiently complete for substantive review, citing concerns with ...
PharmExec13h
Valneva’s Single-Shot Chikungunya Vaccine Demonstrates Durable Immune Response in Children
Results from the Phase II VLA1553-221 trial show that a full dose of Ixchiq demonstrated a 96.5% seroresponse rate in ...
PharmExec20h
GLP-1 Medications Should Be Paired With Healthy Diet and Exercise: Report
While the medications may reduce diet, the best results will be achieved by building healthy habits alongside the drugs.
PharmExec20h
Treating Symptoms to Precision Medicine: The Path Forward
Bharat Awsare discusses a paradigm shift he sees in how the industry is designing and discovering new treatments.